Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome

Background/Aims: A treatment to induce a sustained increase in glomerular filtration rate in patients with hepatorenal syndrome has not yet been identified. Thus, the aim of the present study was to investigate the effecs of terlipressin for 2 days on the glomerular filtration rate in patients with cirrhosis and hepatorenal syndrome. Methods: A double-blind, cross-over randomized study was performed in nine patients. Patients received terlipression (2 mg/day for 2 days) and a placebo for 2 days in a randomized order. Results: Terlipressin administration significantly increased creatinine clearance (from 15±2 ml/min to 27±4 ml/min) and urine output (from 628±67 ml/day to 811±76 ml/day), but did not significantly change urinary sodium concentrations. Urinary sodium excretion was not significantly different after placebo administration (0.6±0.1 mmol/24 h) and terlipressin administration (9.3±7.2 mmol/24 h). Terlipressin administration significantly decreased plasma concentrations of renin and aldosterone but not atrial natriuretic peptide levels. Placebo elicited no significant effects. Conclusions: This study shows that 2-day terlipressin administration increases the glomerular filtration rate in patients with cirrhosis and hepatorenal syndrome.